Organization
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Aliases
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
6 clinical trials
2 abstracts
Clinical trial
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic DermatitisStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of PhototoxicityStatus: Completed, Estimated PCD: 2011-09-20
Clinical trial
Genomic Effects of Glucocorticoids in Patients With Systemic Lupus ErythematosusStatus: Active (not recruiting), Estimated PCD: 2022-05-03
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Gusacitinib in Subjects With Systemic Lupus Erythematosus (SLE)Status: Not yet recruiting, Estimated PCD: 2027-12-30
Abstract
Alteration of mediators of vascular inflammation by anifrolumab in the phase iib muse study in sleOrg: MedImmune, Gaithersburg, MD, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Heart, Lung, and Blood Institute, Bethesda, VA,
Abstract
BASELINE JOINT DAMAGE IS A SIGNIFICANT PREDICTOR OF IMPROVEMENT IN PHYSICAL FUNCTION IN RA PATIENTS AFTER TREATMENTOrg: Centocor, Inc., Kennedy Institute of Rheumatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases,
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Gusacitinib in Subjects With Systemic Lupus Erythematosus (SLE)Status: Not yet recruiting, Estimated PCD: 2027-12-30